MedPath

Treatment of Skin eruptions by Unani medicine Habb e Musaffi Khoon

Phase 3
Not yet recruiting
Conditions
Rash and other nonspecific skin eruption,
Registration Number
CTRI/2019/03/018087
Lead Sponsor
Central Council for Research in Unani Medicine CCRUM New Delhi
Brief Summary

This study is designed as a multicentric open trial in patients with **Busoor-e-Jild (Skin Eruptions).** After screening, Patients will be enrolled if they satisfy inclusion and exclusion criteria. The patients will be treated with Unani pharmacopoeial formulation *Hab-e-Musaffi* *Khoon* four pills daily with water for two weeks.  The patients will be assessed at every week. This includes subjective assessment of general well being and physical examination . The total duration of treatment will be two weeks. Laboratory parameters for safety assessment will be conducted at baseline and on completion of the protocol therapy.

**Composition of *Hab-e-Musaffi Khoon***

| | | | |

| --- | --- | --- | --- |

|**S. No.**

**Ingredients**

**Botanical/Scientific name**

**Quantity**

|

Berg Bakayin

*Melia azedarach* Linn.

10 gm.

|

Berg Neem

*Azadirachta indica* A. Juss.

10 gm.

|

Berg Hina

*Lawsonia alba*

30 gm.

|

Burada Sandal Surkh

*Pterocarpus santalinus* Linn. f.

30 gm.

|

Barhamdandi

*Tricholepis glaberrima* DC.

30 gm.

|

Post Haleela Zard

*Terminalia chebula* Retz.

30 gm.

|

Chaksu

*Cassia absus* Linn.

30 gm.

|

Rasaut (extract)

*Berberis aristata* DC.

30 gm.

|

Zeera Safaid

*Cuminum cyminum* Linn.

10 gm.

|

Sarphoka

*Tephrosia purpurea* (L.) Pers.

30 gm.

|

Shahtra

*Fumaria officinalis* Linn.

30 gm.

|

Filfil Siyah

*Piper nigrum* Linn.

10 gm.

|

Kishneez Khushk

*Coriandrum sativum* Linn.

30 gm.

|

Post Kachnal

*Bauhinia variegata* Linn.

10 gm.

|

Gul-e-Surkh

*Rosa damascena* Mill.

30 gm.

|

Neelkanthi

*Ajuga bracteosa* Wall. ex Benth.

30 gm.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
240
Inclusion Criteria
  • The following criteria will be strictly followed for inclusion of cases in an observational study.
  • 1.Patients of either sex in the age group of 15 to 60 years.
  • 2.Occurrence of the following (5-15 in number): i.Vesicles (a vesicle is a small blister, as on the skin.
  • Vesicles are less than 0.5 centimeters in diameter) ii.Papules (Small solid rounded bumps rising from the skin that are each usually less than 1 centimeter in diameter (less than 3/8 inch across) iii.Pustules (Small solid rounded bumps rising from the skin that are each usually less than 1 centimeter in diameter (less than 3/8 inch across) iv.Macules (Flat , distinct, colored area of the skin less than 1 cm in diameter).
Exclusion Criteria

The patients of Busoor-e-Jild (Skin Eruptions) with following conditions will be excluded from the study: 1.Age <15 years and >60 years 2.Pregnancy and Lactation 3.Patients with disorders requiring long term treatment 4.Patients with more than 15 skin eruptions 5.Size of skin eruption more than 1cm 6.Eruptions due to viral diseases (Chicken pox, Measles, Herpes) 7.Patients with other inflammatory skin conditions like localized abscess/ carbuncles/ boils.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement in signs and symptoms of Busoor-e-Jild (Skin Eruptions)Two weeks
Secondary Outcome Measures
NameTimeMethod
Haematological and biochemical assessment for safety assessmentInvestigations will be done at baseline and end of treatment

Trial Locations

Locations (1)

Regional Research Institute of Unani Medicine (RRIUM)

🇮🇳

Bhadrak, ORISSA, India

Regional Research Institute of Unani Medicine (RRIUM)
🇮🇳Bhadrak, ORISSA, India
Dr Akhter Hussain Jamali
Principal investigator
8811907160
crukxj522@gmail.com
Dr Rahat Raza
Principal investigator
9911315309
rridelhi@gmail.com
Dr Syed Abdullah Hussaini
Principal investigator
06784251289
rriumbdk_unani@yahoo.co.in

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.